

Resource Summary Report

Generated by [dkNET](#) on Aug 7, 2026

FITC anti-human CD3

RRID:AB_314060

Type: Antibody

Proper Citation

BioLegend Cat# 300406, RRID:AB_314060

Antibody Information

URL: http://antibodyregistry.org/AB_314060

Proper Citation: BioLegend Cat# 300406, RRID:AB_314060

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone UCHT1

Antibody ID: AB_314060

Vendor: BioLegend

Catalog Number: 300406

Alternative Catalog Numbers: 300405, 300452, 300440

Record Creation Time: 20250820T035418+0000

Record Last Update: 20250820T173014+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD3.

No alerts have been found for FITC anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 43 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Lu M, et al. (2026) Homeostatic maturation programs drive human cDC2s into a tolerogenic state. *Immunity*, 59(5), 1201.

Sobu R, et al. (2026) IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model. *iScience*, 29(7), 116386.

Schenk TJC, et al. (2026) Activation phenotypes defined by the coordinated expression of activation markers discriminate TCR-mediated and bystander T cell responses. *iScience*, 29(2), 114551.

Calaud C, et al. (2026) Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-azacitidine against diffuse large B-cell lymphoma. *Blood neoplasia*, 3(2), 100214.

Wang Z, et al. (2026) Pluripotent stem cell-derived CAR-NK progenitor therapy targets minimal residual disease and prevents relapse in leukemia models. *Cell stem cell*, 33(3), 405.

Brennan K, et al. (2026) Circulating natural killer cells are phenotypically and functionally altered in age-related macular degeneration. *Cell reports. Medicine*, 7(6), 102792.

Ritchie TM, et al. (2025) The impact of oral cannabis consumption during pregnancy on maternal spiral artery remodelling, fetal growth and offspring behaviour in mice. *EBioMedicine*, 114, 105572.

Cao B, et al. (2025) CV1-secreting sCAR-T cells potentiate the abscopal effect of microwave ablation in heterogeneous tumors. *Cell reports. Medicine*, 6(2), 101965.

Chen Z, et al. (2025) YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies. *Cell*, 188(2), 331.

Oka T, et al. (2025) Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer. *Cell reports*, 44(5), 115561.

Vu LT, et al. (2024) Single-cell transcriptomics of the immune system in ME/CFS at baseline and following symptom provocation. *Cell reports. Medicine*, 5(1), 101373.

Wang Q, et al. (2024) Galectin-3 induces pathogenic immunosuppressive macrophages through interaction with TREM2 in lung cancer. *Journal of experimental & clinical cancer research* : CR, 43(1), 224.

Ni Y, et al. (2024) Human yolk sac-derived innate lymphoid-biased multipotent progenitors emerge prior to hematopoietic stem cell formation. *Developmental cell*, 59(19), 2626.

Cui T, et al. (2024) Dynamic immune landscape in vaccinated-BA.5-XBB.1.9.1 reinfections revealed a 5-month protection-duration against XBB infection and a shift in immune imprinting. *EBioMedicine*, 99, 104903.

Liu C, et al. (2024) Protocol for in vitro generation of innate lymphoid cells from human embryonic tissues. *STAR protocols*, 6(1), 103525.

Sjögren T, et al. (2024) Single cell characterization of blood and expanded regulatory T cells in autoimmune polyendocrine syndrome type 1. *iScience*, 27(4), 109610.

Sun J, et al. (2024) Metabolic regulator LKB1 controls adipose tissue ILC2 PD-1 expression and mitochondrial homeostasis to prevent insulin resistance. *Immunity*, 57(6), 1289.

Watson SS, et al. (2024) Fibrotic response to anti-CSF-1R therapy potentiates glioblastoma recurrence. *Cancer cell*, 42(9), 1507.

Cui L, et al. (2024) Targeting Arachidonic Acid Metabolism Enhances Immunotherapy Efficacy in ARID1A-Deficient Colorectal Cancer. *Cancer research*.

Valeri E, et al. (2024) A novel STING variant triggers endothelial toxicity and SAVI disease. *The Journal of experimental medicine*, 221(9).